Screening for M220 mutation in azole-resistant Aspergillus fumigatus isolates from clinical and environmental specimens in Cuba

Authors

  • Javier Luis San Juan Galán Institute of Tropical Medicine "Pedro Kourí" https://orcid.org/0000-0001-5943-715X
  • Carlos Manuel Fernández Andreu Institute of Tropical Medicine "Pedro Kourí"
  • Gerardo Félix Martínez Machín Institute of Tropical Medicine "Pedro Kourí"
  • Mayda Rosa Perurena Lancha Institute of Tropical Medicine "Pedro Kourí"
  • María Teresa Illnait Zaragozí Institute of Tropical Medicine "Pedro Kourí" https://orcid.org/0000-0002-8929-6172
  • Rosario Esperanza Velar Martínez Institute of Tropical Medicine "Pedro Kourí"

DOI:

https://doi.org/10.6092/issn.2531-7342/12759

Keywords:

triazoles, Etest, drug resistance, CYP51A, sequencing

Abstract

Aspergillosis is a fungal disease caused by different Aspergillus species and have high morbidity/mortality rates. Aspergillus fumigatus is the main aetiological agent related to most of Aspergillus infections. The use of triazoles is recommended as first line of treatment, however, the reports of azole-resistant A. fumigatus due to mutations in CYP51 have increased around the world. The goals were to determine the antifungal susceptibility patterns for triazoles in thirty A. fumigatus isolates from clinical and environmental samples and to detect mutation M220 in the resistant ones. Determination of minimum inhibitory concentrations of every isolate was performed by using the Etest commercial method for itraconazole, voriconazole and posaconazole. For the resistant isolates, a PCR was performed for amplifying a 173 bp fragment of cyp51A and the resulting amplicons were sequenced. Nine out of 30 isolates were resistant to itraconazole and none were resistant to voriconazole or posaconazole. The alignment of sequences with a CYP51 A. fumigatus wild type strain did not show any modifications at codon 220. Other molecular mechanisms of resistance are probably related to the resistant phenotypes isolated.

References

Almaguer M, Aira MJ, Rodríguez-Rajo FJ, Rojas TI (2013) Study of airborne fungus spores by viable and non-viable methods in Havana, Cuba. Grana 52(4):289-298. https://doi.org/10.1080/00173134.2013.829869

Anonymous (2017) The burden of fungal disease: new evidence to show the scale of the problem across the globe. LIFE [Online]. Available: http://go.nature.com/2sMKpuN

Arikan-Akdagli S, Ghannoum M, Meis JF (2018) Antifungal resistance: specific focus on multidrug resistance in Candida auris and secondary azole resistance in Aspergillus fumigatus. Journal of Fungi 4(129):1-13. https://doi.org/10.3390/jof4040129

Badiee P, Alborzi A, Moeini M, Haddadi P, Farshad S, Japoni A, Ziyaeyan M (2012) Antifungal susceptibility of the Aspergillus species by etest and CLSI reference methods. Archives of Iranian Medicine 15(7):429-432.

Beltrán-Rodríguez N, San Juan-Galán JL, Fernández-Andreu CM, Yera DM, Pita MB, Perurena-Lancha MR, Velar-Martínez R, Illnait-Zaragozí MT, Martínez-Machín GF (2019) Chronic pulmonary aspergillosis in patients with underlying respiratory disorders in Cuba - a pilot study. Journal of Fungi 5(18):1-8. https://doi.org/10.3390/jof5010018

Berger S, El-Chazli Y, Babu AF, Coste AT (2017) Azole resistance in Aspergillus fumigatus: a consequence of antifungal use in agriculture? Frontiers in Microbiology 8(1024):1-6. https://doi.org/10.3389/fmicb.2017.01024

Bonifaz JA (2015) Micología Médica Básica. McGraw-Hill, México D. F., México.

Brown GD, Denning DW, Gow NA, Levitz SM, Netea MG, White TC (2012) Hidden killers: human fungal infections. Science Translational Medicine 4(165):165rv113. https://doi.org/10.1126/scitranslmed.3004404

Buil JB, Hagen F, Chowdary A, Verweij PE, Meis JF (2018) Itraconazole, voriconazole, and posaconazole CLSI MIC distributions for wild-type and azole-resistant Aspergillus fumigatus isolates. Journal of Fungi 4(103):1-9. https://doi.org/10.3390/jof4030103

Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, Keniya MV, Tanabe K, Niimi M, Goffeau A, Monk BC (2009) Efflux-mediated antifungal drug resistance. Clinical Microbiology Review 22(2):291-321. https://doi.org/10.1128/CMR.00051-08

Chandrasekar PH, Manavathu EK (2009) Antifungal resistance: Aspergillus. In: Antimicrobial Drug Resistance (Mayers DL ed). Humana Press, New York, pp 953-965.https://doi.org/10.1007/978-1-60327-595-8_19

Costa C, Dias PJ, Sa-Correia I, Teixeira MC (2014) MFS multidrug transporters in pathogenic fungi: do they have real clinical impact? Frontiers in Physiology 5(197):1-8. https://doi.org/10.3389/fphys.2014.00197

Cuba GdlRd (2016) Lista oficial de plaguicidas autorizados. Plaguicidas RCd (16):147.

Fisher MC, Hawkins NJ, Sanglard D, Gurr SJ (2018) Worldwide emergence of resistance to antifungal drugs challenges human health and food security. Science 360(6390):739-742. https://doi.org/10.1126/science.aap7999

Gonçalves SS (2016) Global aspects of triazole resistance in Aspergillus fumigatus with focus on Latin American countries. Journal of Fungi 3(5):1-10. https://doi.org/10.3390/jof3010005

Gonҫalves SS, Souza ACR, Chowdhary A, Meis JF, Colombo AL (2016) Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus. Mycoses 59: 198-219. https://doi.org/10.1111/myc.12469

Jenks JD, Hoenigl M (2018) Treatment of aspergillosis. Journal of Fungi 4(98):1-17. https://doi.org/10.3390/jof4030098

Lopetegui CM, Menéndez GMM, Pérez YT, López ME, Castillo EMG (2006) Aplicaciones de la aerobiología en el sistema de predicción y vigilancia de la enfermedad moho azul del tabaco en la provincia Pinar del Río, Cuba. Avances 8(4):1-11.

Maertens JA (2004) History of the development of azole derivatives. Clinical Microbiology and Infection 10(1):1-10. https://doi.org/10.1111/j.1470-9465.2004.00841.x

Magyar D, Vass M, Li DW (2016) Dispersal Strategies of Microfungi. In: Biology of Microfungi (Li D-W ed) Springer International Publishing, Switzerland, pp 315-371. https://doi.org/10.1007/978-3-319-29137-6_14

Morales Ojeda R (2018) Cuadro básico de medicamentos y productos naturales. MINSAP (Resolución No. 536):1-38.

Prasad R, Shah AH, Rawal MK (2016) Antifungals: mechanism of action and drug resistance. In: Advances in experimental medicine and biology (Ramos J, ed) Springer International Publishing, Switzerland, 22. https://doi.org/10.1007/978-3-319-25304-6_14

Rivero-Menendez O, Alastruey-Izquierdo A, Mellado E, Cuenca-Estrella M (2016) Triazole resistance in Aspergillus spp.: a worldwide problem? Journal of Fungi 2(21):1-20. https://doi.org/10.3390/jof2030021

Samson RA, Hong S, Peterson SW, Frisvad JC, Varga J (2007) Polyphasic taxonomy of Aspergillus section Fumigati and its teleomorph Neosartorya. Studies in Mycology 59:147-203. https://doi.org/10.3114/sim.2007.59.14

Samson RA, Visagie CM, Houbraken J, Hong SB, Hubka V, Klaassen CHW, Perrone G, Seifert KA, Susca A, Tanney JB, Varga J, Kocsubé S, Szigeti G, Yaguchi T, Frisvad JC (2014) Phylogeny, identification and nomenclature of the genus Aspergillus. Studies in Mycology 78:141-173. https://doi.org/10.1016/j.simyco.2014.07.004

Sanglard D (2016) Emerging threats in antifungal-resistant fungal pathogens. Frontiers in Medicine 3(11):1-10. https://doi.org/10.3389/fmed.2016.00011

San Juan-Galán JL, Fernández-Andreu CM, Martínez-Machín G, Perurena-Lancha MR, Velar-Martínez R, Illnait-Zaragozí MT (2017a) Emergencia en Cuba de especies de Aspergillus resistentes a antifúngicos. Boletín Epidemiológico IPK 27(13):97-104.

San Juan-Galán JL, Fernández-Andreu CM, Almaguer M, Perurena-Lancha MR, Martínez-Machín G, Velar-Martínez R, Illnait-Zaragozí MT (2017b) Susceptibilidad in vitro de cepas cubanas de Aspergillus de origen clínico y ambiental. Biomédica 37(4):452-459. http://www.scielo.org.co/pdf/bio/v37n4/0120-4157-bio-37-04-00452.pdf

Snelders E, Camps SMT, Karawajczyk A, Schaftenaar G, Kema GHJ, van der Lee HA, Klaassen CH, Melchers WJG, Verweij PE (2012) Triazole fungicides can induce cross-resistance to medical triazoles in Aspergillus fumigatus. PLoS ONE 7(3):1-11. https://doi.org/10.1371/journal.pone.0031801

Spiess B, Seifarth W, Merker N, Howard SJ, Reinwald M, Dietz A, Hofmann WK, Buchheidt D (2012) Development of novel PCR assays to detect azole resistance mediating mutations of the Aspergillus fumigatus cyp51A gene in primary clinical samples from neutropenic patients. Antimicrobial Agents and Chemotherapy 56(7):3905-3910. https://doi.org/10.1128/AAC.05902-11

Sweileh WM, Sawalha AF, Al-Jabi S, Zyoud SH (2017) Bibliometric analysis of literature on antifungal triazole resistance: 1980–2015. Germs 7(1):19-27. https://doi.org/10.18683/germs.2017.1104

Verweij PE, Lestrade PPA, Melchers WJG, Meis JF (2016) Azole resistance surveillance in Aspergillus fumigatus: beneficial or biased? Journal of Antimicrobial Chemotherapy 71(8):2079-2082. https://doi.org/10.1093/jac/dkw259

Downloads

Published

2021-06-25

How to Cite

San Juan Galán, J. L., Fernández Andreu, C. M., Martínez Machín, G. F., Perurena Lancha, M. R., Illnait Zaragozí, M. T., & Velar Martínez, R. E. (2021). Screening for M220 mutation in azole-resistant Aspergillus fumigatus isolates from clinical and environmental specimens in Cuba. Italian Journal of Mycology, 50, 44–51. https://doi.org/10.6092/issn.2531-7342/12759

Issue

Section

Articles